Citation Impact
Citing Papers
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
2008
rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data
2014 Standout
Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
2010
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
2011
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
2015
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
2013
Direct stimulation of NADP + synthesis through Akt-mediated phosphorylation of NAD kinase
2019 Science
miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma
2012
Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
2017
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
2016
Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation
2008
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model
2012
ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
2010
Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification
2010
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
2011
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
2016
The hVps34‐ SGK 3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC 1 and tumour growth
2016
New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
2011
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
2011
Metastatic tumor evolution and organoid modeling implicate TGFBR2as a cancer driver in diffuse gastric cancer
2014
mTOR Signaling in Growth Control and Disease
2012 Standout
The FGF family: biology, pathophysiology and therapy
2009 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
The MET receptor tyrosine kinase in invasion and metastasis
2007
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
WNT signalling pathways as therapeutic targets in cancer
2012 Standout
Lung Cancer
2008 Standout
The MET axis as a therapeutic target
2009
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Inhibition of Basal FGF Receptor Signaling by Dimeric Grb2
2012
The Cancer Genome Atlas Pan-Cancer analysis project
2013 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Akti-1/2, an allosteric inhibitor of Akt 1 and 2, efficiently inhibits CaMKIα activity and aryl hydrocarbon receptor pathway
2010
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
2012
The molecular biology of head and neck cancer
2010 Standout
Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities
2021 Standout
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
2011
Lung cancer: current therapies and new targeted treatments
2016 Standout
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Drug development of MET inhibitors: targeting oncogene addiction and expedience
2008
Akt inhibitors in clinical development for the treatment of cancer
2010
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Targeting apoptosis in cancer therapy
2020 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Cancer as an overhealing wound: an old hypothesis revisited
2008 Standout
MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort
2008
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer
2013
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
2015
Cancer gene discovery in hepatocellular carcinoma
2010
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
2008
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer
2012
Showering c-MET-dependent cancers with drugs
2008
Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
2013
Akt signalling in health and disease
2011 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
The functions and regulation of the PTEN tumour suppressor
2012 Standout
The PI3K Pathway in Human Disease
2017 Standout
Cancer-related inflammation and treatment effectiveness
2014 Standout
AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
2016
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
A Switch from Canonical to Noncanonical Wnt Signaling Mediates Drug Resistance in Colon Cancer Cells
2011
Modeling Development and Disease with Organoids
2016 Standout
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
2015
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Disruption of Immune Homeostasis in Human Dendritic Cells via Regulation of Autophagy and Apoptosis by Porphyromonas gingivalis
2019
The Fibroblast Growth Factor signaling pathway
2015 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Macrophage Polarization
2016 Standout
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
2013
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
2012
MET As a Possible Target for Non–Small-Cell Lung Cancer
2013
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
2009
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
2013
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
2017
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
2010
Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes
2011
Kinase Drug Discovery – What’s Next in the Field?
2012
Cancer Genome Landscapes
2013 StandoutScience
Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)
2010
Role of FGF Receptors as an Emerging Therapeutic Target in Lung Squamous Cell Carcinoma
2013
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal
2014 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma
2015
Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
2015
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
2011
A kinase-independent function of AKT promotes cancer cell survival
2014
Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells
2014
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
2009
Works of Harold Hatch being referenced
Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival
2007
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
2010 Standout
FGFR2 -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
2008
Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor
2009